BioSig (BSGM) 10-Q 14 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 14, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		20,950,093
Amendment Flag	false
Entity Central Index Key	1,530,766
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash	$ 150,454	$ 953,234
Prepaid expenses	134,530	31,308
Total current assets	284,984	984,542
Property and equipment, net	22,692	18,408
Other assets:
Deposits	27,612	27,612
Total assets	335,288	1,030,562
Current liabilities:
Accounts payable and accrued expenses, including $8,703 and $12,716 to related parties as of September 30, 2016 and December 31, 2015, respectively	426,497	223,546
Dividends payable	341,403	340,291
Warrant liability	2,324,460	1,621,199
Derivative liability	291,086	285,157
Total current liabilities	3,383,446	2,470,193
Series C Preferred Stock, 1,090 and 1,471 shares issued and outstanding; liquidation preference of $1,090,000 and $1,471,000 as of September 30, 2016 and December 31, 2015, respectively	1,090,000	1,471,000
Stockholders’ deficit
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B and 4,200 shares of Series C Preferred Stock	0	0
Common stock, $0.001 par value, authorized 50,000,000 shares, 20,935,093 and 16,825,703 issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	20,935	16,826
Additional paid in capital	38,295,183	29,314,399
Accumulated deficit	(42,454,276)	(32,241,856)
Total stockholders’ deficit	(4,138,158)	(2,910,631)
Total liabilities and stockholders’ deficit	$ 335,288	$ 1,030,562

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Accounts payable and accrued expenses, related parties (in Dollars)	$ 8,703	$ 12,716
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	20,935,093	16,825,703
Common stock, shares outstanding	20,935,093	16,825,703
Series C Preferred Stock [Member]
Preferred stock, shares issued	1,090	1,471
Preferred stock, shares outstanding	1,090	1,471
Preferred stock, liquidation preference (in Dollars)	$ 1,090,000	$ 1,471,000
Preferred stock, shares authorized	4,200	4,200
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	200
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	600

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating expenses:
Research and development	$ 560,514	$ 354,471	$ 2,139,671	$ 1,146,113
General and administrative	991,852	2,117,010	7,257,852	8,801,878
Depreciation	2,570	2,607	7,811	7,948
Total operating expenses	1,554,936	2,474,088	9,405,334	9,955,939
Loss from operations	(1,554,936)	(2,474,088)	(9,405,334)	(9,955,939)
Other income (expense):
Gain (loss) on change in fair value of derivatives	17,771	2,851,755	(807,087)	3,050,318
Interest income (expense)	0	0	1	(1,298)
Financing costs	0	0	0	(529,704)
Total other income (expense)	17,771	2,851,755	(807,086)	2,519,316
(Loss) income before income taxes	(1,537,165)	377,667	(10,212,420)	(7,436,623)
Income taxes (benefit)	0	0	0	0
Net (loss) income	(1,537,165)	377,667	(10,212,420)	(7,436,623)
Preferred stock dividend	(24,726)	(53,048)	(85,467)	(244,516)
NET (LOSS) INCOME AVAILABLE TO COMMON STOCKHOLDERS	$ (1,561,891)	$ 324,619	$ (10,297,887)	$ (7,681,139)
Net (loss) income per common share, basic and diluted (in Dollars per share)	$ (0.08)	$ 0.02	$ (0.55)	$ (0.57)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	20,581,041	14,849,127	18,847,515	13,565,453

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT - 9 months ended Sep. 30, 2016 - USD ($)	Embedded Derivative Financial Instruments [Member]Series C Preferred Stock [Member]Additional Paid-in Capital [Member]	Embedded Derivative Financial Instruments [Member]Series C Preferred Stock [Member]	Settlement of Series C Preferred Stock and Accrued Dividends [Member[Series C Preferred Stock [Member]Common Stock [Member]	Settlement of Series C Preferred Stock and Accrued Dividends [Member[Series C Preferred Stock [Member]Additional Paid-in Capital [Member]	Settlement of Series C Preferred Stock and Accrued Dividends [Member[Series C Preferred Stock [Member]	Series C Preferred Stock [Member]Common Stock [Member]	Series C Preferred Stock [Member]Additional Paid-in Capital [Member]	Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2015									$ 16,826	$ 29,314,399	$ (32,241,856)	$ (2,910,631)
Balance (in Shares) at Dec. 31, 2015									16,825,703			16,825,703
Sale of common stock									$ 2,208	3,051,660		$ 3,053,868
Sale of common stock (in Shares)									2,208,514			2,208,514
Common stock issued for services									$ 1,335	2,469,715		$ 2,471,050
Common stock issued for services (in Shares)									1,335,000
Common stock issued upon conversion of preferred stock and accrued dividends			$ 53	$ 84,302	$ 84,355	$ 254	$ 380,746	$ 381,000
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)			53,331			254,000
Reclassify fair value of derivative liability to equity upon conversion of Series C Preferred Stock to common shares	$ 97,897	$ 97,897										97,897
Stock based compensation									$ 259	2,981,931		2,982,190
Stock based compensation (in Shares)									258,545
Preferred Stock dividend										(85,467)		(85,467)
Net loss											(10,212,420)	(10,212,420)
Balance at Sep. 30, 2016									$ 20,935	$ 38,295,183	$ (42,454,276)	$ (4,138,158)
Balance (in Shares) at Sep. 30, 2016									20,935,093			20,935,093

CONDENSED STATEMENT OF STOCKHO6

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals) - Series C Preferred Stock [Member] - Additional Paid-in Capital [Member]	Sep. 30, 2016$ / shares
Preferred stock issued	$ 1.50
Settlement of Series C Preferred Stock and Accrued Dividends [Member[
Preferred stock issued	$ 1.58

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,212,420)	$ (7,436,623)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	7,811	7,948
Amortization of debt discount	0	585,324
Change in derivative liabilities	807,087	(3,050,318)
Equity based compensation	5,453,240	6,907,423
Changes in operating assets and liabilities:
Prepaid expenses	(103,222)	(8,141)
Accounts payable	202,534	(213,754)
Stock based payable	0	(226,305)
Deferred rent payable	417	2,713
Net cash used in operating activities	(3,844,553)	(3,431,733)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(12,095)	(8,971)
Payment of long term deposit	0	(2,612)
Net cash used in investing activity	(12,095)	(11,583)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	3,053,868	3,042,213
Proceeds from sale of Series C preferred stock	0	450,000
Proceeds from exercise of options	0	20,900
Proceeds from exercise of warrants	0	24,981
Net cash provided by financing activities	3,053,868	3,538,094
Net (decrease) increase in cash and cash equivalents	(802,780)	94,778
Cash and cash equivalents, beginning of the period	953,234	239,781
Cash and cash equivalents, end of the period	150,454	334,559
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	0	1,298
Cash paid during the period for income taxes	0	0
Series C Preferred Stock [Member]
Non-cash investing and financing activities:
Common stock issued upon conversion of Series C Preferred Stock and accrued dividends	$ 465,355	$ 1,654,811

NOTE 1 - NATURE OF OPERATIONS A

NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2016
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The condensed balance sheet as of December 31, 2015 has been derived from audited financial statements. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of results that may be expected for the year ending December 31, 2016. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015 filed with the Company’s Form 10-K with the Securities and Exchange Commission on March 14, 2016.

NOTE 2 - GOING CONCERN AND MANA

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 –GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of September 30, 2016, the Company had cash of $150,454 and working capital deficit (current liabilities in excess of current assets) of $3,098,462 principally due to the inclusion of non-cash derivative and warrant liabilities recorded in current liabilities. In addition, the Company raised approximately $450,000 in October 2016 through the sale of common stock and warrants (See Note 11). As of September 30, 2016, excluding the derivative and warrant liabilities, the Company's working capital deficit would have been $482,916. During the nine months ended September 30, 2016, the Company used net cash in operating activities of $3,844,553. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 2 months. The Company's primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders' deficiencies at September 30, 2016 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable. Accordingly, the accompanying condensed financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed financial statements do not include any adjustment that might result from the outcome of this uncertainty.

NOTE 3 - SUMMARY OF SIGNIFICANT

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 3 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges. At September 30, 2016 and December 31, 2015, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 6 and Note 7). Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $560,514 and $2,139,671 for the three and nine months ended September 30, 2016; and $354,471 and $1,146,113 for the three and nine months ended September 30, 2015, respectively. Net Earnings (Loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of September 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. The Company’s diluted loss per share is the same as the basic loss per share for the three months ended September 30, 2015, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2016 September 30, 2015 Series C convertible preferred stock 726,667 1,238,667 Options to purchase common stock 8,090,190 7,405,190 Warrants to purchase common stock 8,333,235 6,372,677 Totals 17,150,092 16,474,467 Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. As of September 30, 2016, the Company had 8,090,190 options outstanding to purchase shares of common stock, of which 6,745,099 were vested. As of December 31, 2015, the Company had 7,780,190 options outstanding to purchase shares of common stock, of which 5,613,501 were vested. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. Registration Rights The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations. On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission. As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements. During the year ended December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations. Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement Reclassification Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses. Recent Accounting Pronouncements There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment as of September 30, 2016 and December 31, 2015 is summarized as follows: September 30, 2016 December 31, 2015 Computer equipment $ 80,544 $ 68,449 Furniture and fixtures 10,117 10,117 Subtotal 90,661 78,566 Less accumulated depreciation (67,969 ) (60,158 ) Property and equipment, net $ 22,692 $ 18,408 Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Depreciation expense was $2,570 and $7,811 for the three and nine months ended September 30, 2016, respectively; and $2,607 and $7,948 for the three and nine months ended September 30, 2015, respectively.

NOTE 5 - ACCOUNTS PAYABLE AND A

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at September 30, 2016 and December 31, 2015 consist of the following: September 30, 2016 December 31, 2015 Accrued accounting and legal $ 185,630 $ 112,723 Accrued reimbursements - 13,613 Accrued consulting 3,500 15,200 Accrued research and development expenses 177,577 34,179 Accrued office and other 7,190 31,482 Accrued payroll 35,835 - Deferred rent 3,432 3,016 Accrued settlement related to arbitration 13,333 13,333 $ 426,497 $ 223,546

NOTE 6 - SERIES C 9% CONVERTIBL

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK	9 Months Ended
	Sep. 30, 2016
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 6 – SERIES C 9% CONVERTIBLE PREFERRED STOCK On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”). The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder. In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including: ● incur additional indebtedness; ● permit liens on assets; ● repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock; ● pay cash dividends to our stockholders; and ● engage in transactions with affiliates. Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection. In the event that: (i) we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered, (ii) we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered, (iii) we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv) we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered, (v) we are party to a change of control transaction, (vi) we file for bankruptcy or a similar arrangement or are adjudicated insolvent, (vii) we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days, The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%. The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C Preferred Stock outside of equity. In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date. The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301. In accordance with ASC 470-20, at issuance, the Company recognized an embedded beneficial conversion feature present in the Series C Preferred Stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital. The aggregate debt discount, comprised of the relative intrinsic value of the conversion option ($1,303,671), the relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590), for a total of $2,781,000, is amortized over an estimated one year as interest expense. During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company’s Series C Preferred Stock. During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C Preferred Stock for net proceeds of $1,814,910. At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required. There was no established market for the Company’s common stock. As described in Note 7, as of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities. At March 31, 2015, the Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: contractual terms of 2.78 to 3.50 years, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141.00%. In February 2016, the Company issued an aggregate of 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends. In May 2016, the Company issued an aggregate of 197,714 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends. In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends. For the nine months ended September 30, 2016, at the time of conversions, the Company reclassified the fair value of the embedded beneficial conversion feature of the Series C Preferred Stock of $97,897 from liability to equity. The fair values were determined using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.23% to 0.59%, a dividend yield of 0%, and volatility of 141% to 150%. Series C Preferred Stock issued and outstanding totaled 1,090 and 1,471 as of September30, 2016 and December 31, 2015, respectively. As of September 30, 2016 and December 31, 2015, the Company has accrued $341,403 and $340,291 dividends payable on the Series C Preferred Stock. Registration Rights Agreement In connection with the Company’s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount. Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events. The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014. As a result, the Company accrued $55,620 as interest expense for liquidating damages due under the registration rights agreement as of December 31, 2014. At December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.

NOTE 7 - WARRANT AND DERIVATIVE

NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES	9 Months Ended
	Sep. 30, 2016
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 7 – WARRANT AND DERIVATIVE LIABILITIES At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required. There was no established market for the Company’s common stock. As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively. The Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89, a dividend yield of 0%, and volatility of 141.00%. At September 30, 2016, the Company marked to market the fair value of the reset provisions of the Series C Preferred Stock and warrants and determined fair values of $291,086 and $2,324,460, respectively. The Company recorded a gain(loss) from change in fair value of derivatives of $17,771 and $(807,087) for the three and nine months ended September 30, 2016. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 0.49 to 3.61 years, a risk free interest rate of 0.39% to 1.01%, a dividend yield of 0%, and volatility of 143.00% to 152.00%.

NOTE 8 - STOCKHOLDER EQUITY

NOTE 8 - STOCKHOLDER EQUITY	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 – STOCKHOLDER EQUITY Preferred stock The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of September 30, 2016 and December 31, 2015, the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock and 4,200 shares of Series C Preferred Stock. As of September 30, 2016 and December 31, 2015, there were no outstanding shares of Series A and Series B preferred stock. In February 2016, the Company issued 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends. In May 2016, the Company issued an aggregate of 197,714 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends. In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends. As of September 30, 2016 and December 31, 2015, the Company has 1,090 and 1,471 Series C Preferred Stock issued and outstanding. Common stock The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. As of September 30, 2016 and December 31, 2015, the Company had 20,935,093 and 16,825,703 shares issued and outstanding, respectively. During the nine months ended September 30, 2016, the Company issued an aggregate of 790,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $1,419,200 ($1.80 average per share). During the nine months ended September 30, 2016, the Company issued an aggregate of 545,000 shares of common stock for services rendered totaling $1,051,850 ($1.93 average per share). During the nine months ended September 30, 2016, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,208,514 shares of common stock and 1,254,550 warrants for aggregate proceeds of $3,053,868, net of $278,188 in expenses. During the nine months ended September 30, 2016, the Company issued 175,000 shares of common stock as vested previously issued restricted stock units During the nine months ended September 30, 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan. The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions: dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84. Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement The registration rights agreements require the Company to file a registration statement within 45 calendar days of the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on April 29, 2016. On August 2, 2016, the Company filed Form S-1 registration statement which became effective August 9, 2016. The Company has estimated the liability under the registration rights agreement at $-0- as of September 30, 2016.

NOTE 9 - OPTIONS, RESTRICTED ST

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS	9 Months Ended
	Sep. 30, 2016
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 9 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Options On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 11,686,123 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith. Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. The Company reserved 227,388 shares of its common stock for future issuance under the terms of the Plan. During the nine months ended September 30, 2016, the Company granted an aggregate of 750,000, net of 100,000 canceled, options to officers, directors and key consultants. During the nine months ended September 30, 2016, the Company granted an aggregate of 873,545 stock grants to officers, employees and key consultants under the plan. See Note 8. The following table presents information related to stock options at September 30, 2016: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 2,139,642 6.8 1,572,642 2.01-3.00 5,650,548 5.6 4,872,457 3.01-4.00 300,000 8.5 300,000 8,090,190 6.0 6,745,099 A summary of the stock option activity and related information for the Plan for the nine months ended September 30, 2016 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2016 7,780,190 $ 2.30 6.4 $ - Grants 750,000 1.80 10.0 - Exercised - Forfeiture/Canceled (440,000 ) $ 2.24 - - Outstanding at September 30, 2016 8,090,190 $ 2.26 6.0 $ 12,350 Exercisable at September 30, 2016 6,745,099 $ 2.31 6.0 $ 3,563 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.52 as of September 30, 2016, which would have been received by the option holders had those option holders exercised their options as of that date. Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from using the Company’s historical stock prices for 2016. Prior to 2016, the Company derived the volatility figure from an index of historical stock prices for comparable entities. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period. The Company estimated forfeitures related to option grants at a weighted average annual rate of 0% per year, as the Company does not yet have adequate historical data, for options granted during the nine months ended September 30, 2016 and 2015. The following assumptions were used in determining the fair value of employee and vesting non-employee options during the nine months ended September 30, 2016 and 2015: September 30, 2016 September 30, 2015 Risk-free interest rate 1.08% - 1.69 % 1.19% - 2.37 % Dividend yield 0 % 0 % Stock price volatility 122.82 % 118.56% -130.30 % Expected life 5 – 10 years 7-10 years Weighted average grant date fair value $ 1.50 $ 2.41 During the nine months ended September 30, 2016, the Company granted an aggregate of 685,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.84 per share for a term of ten years, vesting immediately. In September 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan. The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions: dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84. On August 24, 2016, the Company granted 65,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.33 per share for a term of ten years with 12,500 vesting immediately; 37,500 vesting quarterly beginning September 14, 2016 through December 14, 2017 and 15,000 performance contingent. The fair value of all options vesting during the three and nine months ended September 30, 2016 of $218,085 and $2,512,886, respectively, and during the three and nine months ended September 30, 2015 of $836,425 and $3,793,152, respectively, was charged to current period operations. Unrecognized compensation expense of $406,988 at September 30, 2016 will be expensed in future periods. Restricted Stock The following table summarizes the restricted stock activity for the nine months ended September 30, 2016: Restricted shares issued as of January 1, 2016 175,000 Granted 180,000 Vested (175,000 ) Total restricted shares issued as of September 30, 2016 180,000 Vested restricted shares as of September 30, 2016 - Unvested restricted shares as of September 30, 2016 180,000 On September 7, 2016, the Company granted 180,000 restricted stock units (“RSU”) to a consultant vesting monthly over one year beginning October 7, 2016. Stock based compensation expense related to restricted stock grants was $70,753 and $124,139 for the three months ended September 30, 2016, respectively; and $100,492 and $238,122 for the three and nine months ended September 30, 2015, respectively. As of September 30, 2016, the stock-based compensation relating to restricted stock of $202,847 remain unamortized and is expected to be amortized over the remaining period of approximately 1 year. Warrants The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at September 30, 2016: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 4,173,017 February 2018 to May 2020 $ 1.84 35,076 January 2020 $ 1.95 1,689,026 October 2018 to September 2019 $ 2.00 100,000 August 2018 $ 2.02 30,755 January 2020 $ 2.10 38,572 June 2019 $ 2.50 100,000 August 2018 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 8,333,235 On February 9, 2016, the Company issued 25,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on February 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 6,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring February 9, 2019 for placement agent services. On March 9, 2016, the Company issued an aggregate of 100,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on March 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 12,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring March 9, 2019 for placement agent services. On April 1, 2016, the Company issued an aggregate of 100,327 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 1, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 18,040 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 1, 2019 for placement agent services. On April 19, 2016, the Company issued an aggregate of 84,980 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 19, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 17,996 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 19, 2019 for placement agent services. On April 29, 2016, the Company issued an aggregate of 567,866 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 29, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued an aggregate of 96,256 warrants to purchase the Company’s common stock at $1.50 per share, expiring between October 23, 2018 through April 29, 2019 for placement agent services. On June 1, 2016, the Company issued an aggregate of 38,572 warrants to purchase the Company’s common stock at $2.10 per share, expiring on June 1, 2019, in connection with the sale of the Company’s common stock. On August 30, 2016, the Company issued an aggregate of 152,513 warrants to purchase the Company’s common stock at $1.95 per share, expiring on August 30, 2019, in connection with the sale of the Company’s common stock. On September 19, 2016, the Company issued an aggregate of 35,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on September 19, 2019, in connection with the sale of the Company’s common stock. Stock based compensation related to warrants issued for services was $641 and $56,930 for the three and nine months ended September 30, 2016, respectively; and $44,464 for the three and nine months ended September 30, 2015. A summary of the warrant activity for the nine months ended September 30, 2016 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2016 7,078,685 $ 2.02 3.0 497,933 Grants 1,254,550 1.90 2.5 - Exercised - Canceled - Outstanding at September 30, 2016 8,333,235 $ 2.00 2.3 $ 665,723 Vested and expected to vest at September 30, 2016 8,333,235 $ 2.00 2.3 $ 665,723 Exercisable at September 30, 2016 8,333,235 $ 2.00 2.3 $ 665,723 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $1.52 as of September 30, 2016, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.

NOTE 10 - FAIR VALUE MEASUREMEN

NOTE 10 - FAIR VALUE MEASUREMENT	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 10 – FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity. As of September 30, 2016 and December 31, 2015, the Company did not have any items that would be classified as level 1 or 2 disclosures. The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 7. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 5 are that of volatility and market price of the underlying common stock of the Company. As of September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges. The derivative and warrant liability as of September 30, 2016, in the amount of $291,086 and $2,324,460, respectively, has a level 3 classification. The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of September 30, 2016: Warrant Liability Derivative Balance, December 31, 2015 $ 1,621,199 $ 285,157 Total (gains) losses Transfers out due to conversion of Series C Preferred Stock - (97,897 ) Mark to market to September 30, 2016 703,261 103,826 Balance, September 30, 2016 $ 2,324,460 $ 291,086 Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016 $ (703,261 ) $ (103,826 ) Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

NOTE 11 - SUBSEQUENT EVENTS

NOTE 11 - SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 11 – SUBSEQUENT EVENTS On October 16, 2016, the Company issued 15,000 shares of its common stock to a consultant for services rendered valued at $22,800. On October 28, 2016, the Company entered into securities purchase agreements with investors, pursuant to which the Company received from subscriptions for the purchase of 346,567 shares of the Company’s common stock and warrants to purchase 173,284 shares of our common stock at $1.50, expiring three years from issuance, for aggregate net cash proceeds of $450,477, after financing costs of $69,373.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges. At September 30, 2016 and December 31, 2015, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 6 and Note 7).
Research and Development Expense, Policy [Policy Text Block]	Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $560,514 and $2,139,671 for the three and nine months ended September 30, 2016; and $354,471 and $1,146,113 for the three and nine months ended September 30, 2015, respectively.
Earnings Per Share, Policy [Policy Text Block]	Net Earnings (Loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of September 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. The Company’s diluted loss per share is the same as the basic loss per share for the three months ended September 30, 2015, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2016 September 30, 2015 Series C convertible preferred stock 726,667 1,238,667 Options to purchase common stock 8,090,190 7,405,190 Warrants to purchase common stock 8,333,235 6,372,677 Totals 17,150,092 16,474,467
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. As of September 30, 2016, the Company had 8,090,190 options outstanding to purchase shares of common stock, of which 6,745,099 were vested. As of December 31, 2015, the Company had 7,780,190 options outstanding to purchase shares of common stock, of which 5,613,501 were vested.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Registration Rights Policy [Policy Text Block]	Registration Rights The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations. On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission. As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements. During the year ended December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations. Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement
Reclassification, Policy [Policy Text Block]	Reclassification Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

NOTE 3 - SUMMARY OF SIGNIFICA20

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2016 September 30, 2015 Series C convertible preferred stock 726,667 1,238,667 Options to purchase common stock 8,090,190 7,405,190 Warrants to purchase common stock 8,333,235 6,372,677 Totals 17,150,092 16,474,467

NOTE 4 - PROPERTY AND EQUIPME21

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of September 30, 2016 and December 31, 2015 is summarized as follows: September 30, 2016 December 31, 2015 Computer equipment $ 80,544 $ 68,449 Furniture and fixtures 10,117 10,117 Subtotal 90,661 78,566 Less accumulated depreciation (67,969 ) (60,158 ) Property and equipment, net $ 22,692 $ 18,408

NOTE 5 - ACCOUNTS PAYABLE AND22

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses at September 30, 2016 and December 31, 2015 consist of the following: September 30, 2016 December 31, 2015 Accrued accounting and legal $ 185,630 $ 112,723 Accrued reimbursements - 13,613 Accrued consulting 3,500 15,200 Accrued research and development expenses 177,577 34,179 Accrued office and other 7,190 31,482 Accrued payroll 35,835 - Deferred rent 3,432 3,016 Accrued settlement related to arbitration 13,333 13,333 $ 426,497 $ 223,546

NOTE 9 - OPTIONS, RESTRICTED 23

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure Text Block Supplement [Abstract]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at September 30, 2016: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 2,139,642 6.8 1,572,642 2.01-3.00 5,650,548 5.6 4,872,457 3.01-4.00 300,000 8.5 300,000 8,090,190 6.0 6,745,099
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity and related information for the Plan for the nine months ended September 30, 2016 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2016 7,780,190 $ 2.30 6.4 $ - Grants 750,000 1.80 10.0 - Exercised - Forfeiture/Canceled (440,000 ) $ 2.24 - - Outstanding at September 30, 2016 8,090,190 $ 2.26 6.0 $ 12,350 Exercisable at September 30, 2016 6,745,099 $ 2.31 6.0 $ 3,563
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following assumptions were used in determining the fair value of employee and vesting non-employee options during the nine months ended September 30, 2016 and 2015: September 30, 2016 September 30, 2015 Risk-free interest rate 1.08% - 1.69 % 1.19% - 2.37 % Dividend yield 0 % 0 % Stock price volatility 122.82 % 118.56% -130.30 % Expected life 5 – 10 years 7-10 years Weighted average grant date fair value $ 1.50 $ 2.41
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock activity for the nine months ended September 30, 2016: Restricted shares issued as of January 1, 2016 175,000 Granted 180,000 Vested (175,000 ) Total restricted shares issued as of September 30, 2016 180,000 Vested restricted shares as of September 30, 2016 - Unvested restricted shares as of September 30, 2016 180,000
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at September 30, 2016: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 4,173,017 February 2018 to May 2020 $ 1.84 35,076 January 2020 $ 1.95 1,689,026 October 2018 to September 2019 $ 2.00 100,000 August 2018 $ 2.02 30,755 January 2020 $ 2.10 38,572 June 2019 $ 2.50 100,000 August 2018 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 8,333,235
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the nine months ended September 30, 2016 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2016 7,078,685 $ 2.02 3.0 497,933 Grants 1,254,550 1.90 2.5 - Exercised - Canceled - Outstanding at September 30, 2016 8,333,235 $ 2.00 2.3 $ 665,723 Vested and expected to vest at September 30, 2016 8,333,235 $ 2.00 2.3 $ 665,723 Exercisable at September 30, 2016 8,333,235 $ 2.00 2.3 $ 665,723

NOTE 10 - FAIR VALUE MEASUREM24

NOTE 10 - FAIR VALUE MEASUREMENT (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of September 30, 2016: Warrant Liability Derivative Balance, December 31, 2015 $ 1,621,199 $ 285,157 Total (gains) losses Transfers out due to conversion of Series C Preferred Stock - (97,897 ) Mark to market to September 30, 2016 703,261 103,826 Balance, September 30, 2016 $ 2,324,460 $ 291,086 Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016 $ (703,261 ) $ (103,826 )

NOTE 2 - GOING CONCERN AND MA25

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)	1 Months Ended	9 Months Ended
	Oct. 31, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]
Cash and Cash Equivalents, at Carrying Value		$ 150,454	$ 334,559	$ 953,234	$ 239,781
Working Capital (Deficit)		(3,098,462)
Net Cash Provided by (Used in) Operating Activities		(3,844,553)	$ (3,431,733)
Subsequent Event [Member]
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]
Proceeds from Issuance of Private Placement	$ 450,000
Working Captial, Excluding Derivative and Warrant Liabilties [Member]
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]
Working Capital (Deficit)		$ 482,916

NOTE 3 - SUMMARY OF SIGNIFICA26

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Research and Development Expense	$ 560,514	$ 354,471	$ 2,139,671	$ 1,146,113
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	8,090,190		8,090,190		7,780,190
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares)	6,745,099		6,745,099
Registration Payment Arrangement, Accrual Carrying Value	$ 0		$ 0		$ 0	$ 55,620
Employee Stock Option [Member]
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	8,090,190		8,090,190		7,780,190
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares)	6,745,099		6,745,099		5,613,501

NOTE 3 - SUMMARY OF SIGNIFICA27

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	17,150,092	16,474,467
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	8,090,190	7,405,190
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	8,333,235	6,372,677
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	726,667	1,238,667

NOTE 4 - PROPERTY AND EQUIPME28

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Depreciation	$ 2,570	$ 2,607	$ 7,811	$ 7,948
Minimum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life			5 years

NOTE 4 - PROPERTY AND EQUIPME29

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 90,661	$ 78,566
Less accumulated depreciation	(67,969)	(60,158)
Property and equipment, net	22,692	18,408
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	80,544	68,449
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 10,117	$ 10,117

NOTE 5 - ACCOUNTS PAYABLE AND30

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$ 185,630	$ 112,723
Accrued reimbursements	0	13,613
Accrued consulting	3,500	15,200
Accrued research and development expenses	177,577	34,179
Accrued office and other	7,190	31,482
Accrued payroll	35,835	0
Deferred rent	3,432	3,016
Accrued settlement related to arbitration	13,333	13,333
	$ 426,497	$ 223,546

NOTE 6 - SERIES C 9% CONVERTI31

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) - USD ($)

Feb. 06, 2013

Jan. 09, 2013

Jun. 30, 2016

May 31, 2016

Feb. 29, 2016

Mar. 31, 2015

Jul. 31, 2013

Sep. 30, 2016

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2015

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares)

1,254,550

Class of Warrant or Right, Outstanding (in Shares)

8,333,235

7,078,685

Temporary Equity, Amortization Period

1 year

Stock Issued During Period, Shares, New Issues (in Shares)

2,208,514

Embedded Derivative, Fair Value of Embedded Derivative Liability

$ 1,242,590

$ 291,086

$ 285,157

Fair Value Assumptions, Expected Term

2 years

Fair Value Assumptions, Expected Dividend Rate

0.00%

0.00%

Fair Value Assumptions, Expected Volatility Rate

141.00%

Conversion of Stock, Shares Issued (in Shares)

54,859

Conversion of Stock, Shares Converted (in Shares)

54,759

197,714

Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity

$ 97,897

Dividends Payable, Current

341,403

340,291

Registration Payment Arrangement, Term

the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.

Registration Payment Arrangement, Accrual Carrying Value

0

$ 55,620

0

Series C Preferred Stock [Member]

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Temporary Equity, Shares Authorized (in Shares)

4,200

Preferred Stock, Dividend Rate, Percentage

9.00%

Temporary Equity, Par Value

$ 1,000

Preferred Stock, Dividend Payment Terms

payable quarterly

Preferred Stock, Voting Rights

The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.

Preferred Stock, Beneficial Ownership Limitation and Covenant, Description

The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:●incur additional indebtedness;●permit liens on assets;●repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;●pay cash dividends to our stockholders; and●engage in transactions with affiliates.

Convertible Preferred Stock, Terms of Conversion

Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.In the event that:(i) we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,(ii) we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,(iii) we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv) we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,(v) we are party to a change of control transaction,(vi) we file for bankruptcy or a similar arrangement or are adjudicated insolvent,(vii) we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.

Temporary Equity, Redemption Price Per Share (in Dollars per share)

$ 1.50

Class of Warrant or Rights, Granted (in Shares)

1,330,627

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 2.61

Warrants, Term of Warrants

5 years

Warrant, Description of Warrant

after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.

Temporary Equity, Liquidation Preference

$ 1,090,000

$ 2,781,000

$ 2,781,000

$ 1,471,000

Stock Issued During Period, Shares, New Issues (in Shares)

2,181

Proceeds from Issuance of Redeemable Preferred Stock

$ 1,814,910

Conversion of Stock, Shares Converted (in Shares)

70

236

75

Temporary Equity, Shares Outstanding (in Shares)

1,090

1,471

Series C Preferred Stock [Member] | Full-Ratchet Anti-Dilution Protection Provision [Member]

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 1.50

Class of Warrant or Right, Outstanding (in Shares)

2,315,301

Bridge Loan [Member] | Series C Preferred Stock [Member]

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

600

Embedded Beneficial Conversion Feature [Member] | Series C Preferred Stock [Member]

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Adjustments to Additional Paid in Capital, Other

1,303,671

Temporary Equity, Liquidation Preference

1,303,671

1,303,671

Warrant [Member]

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Embedded Derivative, Fair Value of Embedded Derivative Liability

$ 4,097,444

Warrant [Member] | Series C Preferred Stock [Member]

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Adjustments to Additional Paid in Capital, Warrant Issued

1,064,739

Temporary Equity, Liquidation Preference

1,064,739

1,064,739

Issuance Costs [Member] | Series C Preferred Stock [Member]

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Temporary Equity, Liquidation Preference

$ 412,590

$ 412,590

Minimum [Member]

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Fair Value Assumptions, Expected Term

2 years 284 days

Fair Value Assumptions, Risk Free Interest Rate

0.56%

Fair Value Assumptions, Expected Volatility Rate

141.00%

Minimum [Member] | Series C Preferred Stock [Member]

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Fair Value Assumptions, Risk Free Interest Rate

0.23%

Maximum [Member]

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Fair Value Assumptions, Expected Term

3 years 6 months

Fair Value Assumptions, Risk Free Interest Rate

0.89%

Fair Value Assumptions, Expected Volatility Rate

150.00%

Maximum [Member] | Series C Preferred Stock [Member]

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

Fair Value Assumptions, Risk Free Interest Rate

0.59%

NOTE 7 - WARRANT AND DERIVATI32

NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)	$ 291,086		$ 1,242,590	$ 291,086		$ 285,157
Derivative Liability, Current (in Dollars)	2,324,460		$ 4,097,444	$ 2,324,460		$ 1,621,199
Fair Value Assumptions, Expected Dividend Rate			0.00%	0.00%
Fair Value Assumptions, Expected Volatility Rate			141.00%
Derivative, Gain (Loss) on Derivative, Net (in Dollars)	17,771	$ 2,851,755		$ (807,087)	$ 3,050,318
Fair Value Assumptions, Expected Term				2 years
Embedded Derivative Financial Instruments [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Derivative Liability, Current (in Dollars)	$ 291,086			$ 291,086
Fair Value Assumptions, Expected Dividend Rate				0.00%
Derivative, Gain (Loss) on Derivative, Net (in Dollars)				$ (103,826)
Minimum [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			0.56%
Fair Value Assumptions, Expected Volatility Rate				141.00%
Fair Value Assumptions, Expected Term			2 years 284 days
Minimum [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate				0.39%
Fair Value Assumptions, Expected Volatility Rate				143.00%
Fair Value Assumptions, Expected Term				178 days
Maximum [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			0.89%
Fair Value Assumptions, Expected Volatility Rate				150.00%
Fair Value Assumptions, Expected Term			3 years 6 months
Maximum [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate				1.01%
Fair Value Assumptions, Expected Volatility Rate				152.00%
Fair Value Assumptions, Expected Term				3 years 222 days

NOTE 8 - STOCKHOLDER EQUITY (De

NOTE 8 - STOCKHOLDER EQUITY (Details) - USD ($)	Oct. 23, 2015	Jan. 09, 2013	Jun. 30, 2016	May 31, 2016	Feb. 29, 2016	Jul. 31, 2013	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized							1,000,000		1,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)							$ 0.001		$ 0.001
Conversion of Stock, Shares Issued					54,859
Conversion of Stock, Shares Converted			54,759	197,714
Common Stock, Shares Authorized							50,000,000		50,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)							$ 0.001		$ 0.001
Common Stock, Shares, Issued							20,935,093		16,825,703
Common Stock, Shares, Outstanding							20,935,093		16,825,703
Stock Issued During Period, Shares, Share-based Compensation, Gross							83,545
Stock Issued During Period, Value, Issued for Services (in Dollars)							$ 2,471,050
Stock Issued During Period, Shares, New Issues							2,208,514
Class of Warrant or Rights, Granted							1,254,550
Proceeds from Issuance or Sale of Equity (in Dollars)							$ 3,053,868
Payments of Stock Issuance Costs (in Dollars)							$ 278,188
Stock Issued During Period, Shares, Other							175,000
Stock Issued During Period, Value, Stock Options Exercised (in Dollars)							$ 100,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate							0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							122.82%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							1.08%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term							5 years
Share Price (in Dollars per share)							$ 1.84
Private Placement, Unit Description	each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock
Registration Rights Agreement, Description	The registration rights agreements require the Company to file a registration statement within 45 calendar days of the final closing under the Private Placement and to be effective 120 calendar days thereafter.
Registration Payment Arrangement, Accrual Carrying Value (in Dollars)							$ 0		$ 0	$ 55,620
2012 Equity Incentive Plan [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross							790,000
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars)							$ 1,419,200
Shares Issued, Price Per Share (in Dollars per share)							$ 1.80
Series A Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized							200		200
Series B Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized							600		600
Series C Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized							4,200		4,200
Conversion of Stock, Shares Converted			70	236	75
Temporary Equity, Shares Issued							1,090		1,471
Temporary Equity, Shares Outstanding							1,090		1,471
Stock Issued During Period, Shares, New Issues						2,181
Class of Warrant or Rights, Granted		1,330,627
Services Provided [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)							$ 1.93
Stock Issued During Period, Shares, Issued for Services							545,000
Stock Issued During Period, Value, Issued for Services (in Dollars)							$ 1,051,850

NOTE 9 - OPTIONS, RESTRICTED 34

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - USD ($)

Sep. 19, 2016

Sep. 07, 2016

Aug. 30, 2016

Aug. 24, 2016

Jun. 01, 2016

Apr. 29, 2016

Apr. 19, 2016

Apr. 01, 2016

Mar. 09, 2016

Feb. 09, 2016

Oct. 19, 2012

Sep. 30, 2016

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

750,000

Share Price (in Dollars per share)

$ 1.84

$ 1.84

$ 1.84

Stock Issued During Period, Shares, Share-based Compensation, Gross

83,545

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

122.82%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.08%

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 1.80

Share-based Compensation (in Dollars)

$ 5,453,240

$ 6,907,423

Class of Warrant or Rights, Granted

1,254,550

Warrant [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation (in Dollars)

$ 641

$ 56,930

9

Warrant [Member] | Private Placement [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share Price (in Dollars per share)

1.52

$ 1.52

$ 1.52

Services Provided [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation (in Dollars)

$ 44,464

Employee Stock Option [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

65,000

Share Price (in Dollars per share)

$ 1.84

$ 1.84

$ 1.84

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Stock Issued During Period, Shares, Share-based Compensation, Gross

83,545

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

100,000

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

122.82%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.08%

Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term

5 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 1.33

Restricted Stock Units (RSUs) [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

1 year

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

180,000

Restricted Stock [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

180,000

Share-based Compensation (in Dollars)

$ 70,753

100,492

$ 124,139

238,122

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)

$ 202,847

$ 202,847

$ 202,847

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

1 year

2012 Equity Incentive Plan [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Gross

790,000

2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

11,686,123

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.

Common Stock, Capital Shares Reserved for Future Issuance

227,388

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

750,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

100,000

Share Price (in Dollars per share)

$ 1.52

$ 1.52

$ 1.52

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate

0.00%

Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 1.84

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation (in Dollars)

$ 218,085

$ 836,425

$ 2,512,886

$ 3,793,152

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)

$ 406,988

$ 406,988

$ 406,988

2012 Equity Incentive Plan [Member] | Employee Stock Option [Member] | Officers, Directors and Key Consultants [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

873,545

Warrants at $1.95 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 1.95

$ 1.95

$ 1.95

Warrants at $1.95 [Member] | Private Placement [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Rights, Granted

567,866

84,980

100,327

100,000

25,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 1.95

$ 1.95

$ 1.95

$ 1.95

$ 1.95

Warrant, Expriation Date

Apr. 29, 2019

Apr. 19, 2019

Apr. 1, 2019

Mar. 9, 2019

Warrants at $1.95 [Member] | Warrants Issued to Placement Agents [Member] | Private Placement [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Rights, Granted

17,996

18,040

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 1.50

$ 1.50

Warrant, Expriation Date

Apr. 19, 2019

Apr. 1, 2019

Feb. 9, 2019

Warrants at $1.95 [Member] | Warrant [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Rights, Granted

35,000

152,513

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 1.95

$ 1.95

Warrants at $1.50 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

1.50

1.50

1.50

Warrants at $1.50 [Member] | Warrants Issued to Placement Agents [Member] | Private Placement [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Rights, Granted

96,256

12,000

6,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 1.50

$ 1.50

$ 1.50

Warrant, Expriation Date

Mar. 9, 2019

Feb. 9, 2019

Warrants at $2.10 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 2.10

$ 2.10

$ 2.10

Warrants at $2.10 [Member] | Warrant [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Rights, Granted

38,572

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 2.10

Warrant, Expriation Date

Jun. 1, 2019

Share-based Compensation Award, Tranche One [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

12,500

Share-based Compensation Award, Tranche Two [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

37,500

Share-based Compensation Award, Tranche Three [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

15,000

Maximum [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

130.30%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.69%

2.37%

Maximum [Member] | 2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

10 years

Maximum [Member] | Warrants at $1.50 [Member] | Warrants Issued to Placement Agents [Member] | Private Placement [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Warrant, Expriation Date

Apr. 29, 2019

Minimum [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

118.56%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.08%

1.19%

Minimum [Member] | Warrants at $1.50 [Member] | Warrants Issued to Placement Agents [Member] | Private Placement [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Warrant, Expriation Date

Oct. 23, 2018

NOTE 9 - OPTIONS, RESTRICTED 35

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	8,090,190	7,780,190
Options Outstanding, Weighted Average Remaining Life	6 years	6 years 146 days
Options Exercisable, Number of Options	6,745,099
Options at $1.01-$2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 1.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 2
Options Outstanding, Number of Options	2,139,642
Options Outstanding, Weighted Average Remaining Life	6 years 292 days
Options Exercisable, Number of Options	1,572,642
Options at $2.01-$3.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 2.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 3
Options Outstanding, Number of Options	5,650,548
Options Outstanding, Weighted Average Remaining Life	5 years 219 days
Options Exercisable, Number of Options	4,872,457
Options at $3.01-$4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 3.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 4
Options Outstanding, Number of Options	300,000
Options Outstanding, Weighted Average Remaining Life	8 years 6 months
Options Exercisable, Number of Options	300,000

NOTE 9 - OPTIONS, RESTRICTED 36

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Options Outstanding, Shares	8,090,190	7,780,190
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 2.26	$ 2.30
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years	6 years 146 days
Options Outstanding, Aggregate Intrinsic Value (in Dollars)	$ 12,350	$ 0
Exercisable at September 30, 2016	6,745,099
Exercisable at September 30, 2016 (in Dollars per share)	$ 2.31
Exercisable at September 30, 2016	6 years
Exercisable at September 30, 2016 (in Dollars)	$ 3,563
Grants	750,000
Grants (in Dollars per share)	$ 1.80
Grants	10 years
Exercised	0
Forfeiture/Canceled	(440,000)
Forfeiture/Canceled (in Dollars per share)	$ 2.24

NOTE 9 - OPTIONS, RESTRICTED 37

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - $ / shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate	1.08%
Dividend yield	0.00%	0.00%
Stock price volatility	122.82%
Expected life	5 years
Weighted average grant date fair value (in Dollars per share)	$ 1.50	$ 2.41
Minimum [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate	1.08%	1.19%
Stock price volatility		118.56%
Expected life	5 years	7 years
Maximum [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate	1.69%	2.37%
Stock price volatility		130.30%
Expected life	10 years	10 years

NOTE 9 - OPTIONS, RESTRICTED 38

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2016shares
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity [Line Items]
Restricted shares issued as of January 1, 2016	175,000
Granted	180,000
Vested	(175,000)
Total restricted shares issued as of September 30, 2016	180,000
Vested restricted shares as of September 30, 2016	0
Unvested restricted shares as of September 30, 2016	180,000

NOTE 9 - OPTIONS, RESTRICTED 39

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Number of Warrants Outstanding	8,333,235	7,078,685
Warrants at $0.001 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 0.001
Number of Warrants Outstanding	383,320
Expiration Date, Warrants	January 2,020
Warrants at $1.50 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.50
Number of Warrants Outstanding	4,173,017
Expiration Date, Warrants	February 2018 to May 2020
Warrants at $1.84 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.84
Number of Warrants Outstanding	35,076
Expiration Date, Warrants	January 2,020
Warrants at $1.95 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.95
Number of Warrants Outstanding	1,689,026
Expiration Date, Warrants	October 2018 to September 2019
Warrants at $2.00 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2
Number of Warrants Outstanding	100,000
Expiration Date, Warrants	August 2,018
Warrants at $2.02 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.02
Number of Warrants Outstanding	30,755
Expiration Date, Warrants	January 2,020
Warrants at $2.10 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.10
Number of Warrants Outstanding	38,572
Expiration Date, Warrants	June 2,019
Warrants at $2.50 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.50
Number of Warrants Outstanding	100,000
Expiration Date, Warrants	August 2,018
Warrants at $2.75 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.75
Number of Warrants Outstanding	228,720
Expiration Date, Warrants	August 2019 to September 2019
Warrants at $3.67 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 3.67
Number of Warrants Outstanding	214,193
Expiration Date, Warrants	December 2018 to January 2019
Warrants at $3.75 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 3.75
Number of Warrants Outstanding	1,340,556
Expiration Date, Warrants	April 2019 to March 2020

NOTE 9 - OPTIONS, RESTRICTED 40

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares	8,333,235	7,078,685
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 2	$ 2.02
Warrants Outstanding, Weighted-Average Remaining Contractual Term	2 years 109 days	3 years
Warrants Outstanding, Aggregate Intrinsic Value (in Dollars)	$ 665,723	$ 497,933
Vested and expected to vest at September 30, 2016	8,333,235
Vested and expected to vest at September 30, 2016 (in Dollars per share)	$ 2
Vested and expected to vest at September 30, 2016	2 years 109 days
Vested and expected to vest at September 30, 2016 (in Dollars)	$ 665,723
Exercisable at September 30, 2016	8,333,235
Exercisable at September 30, 2016 (in Dollars per share)	$ 2
Exercisable at September 30, 2016	2 years 109 days
Exercisable at September 30, 2016 (in Dollars)	$ 665,723
Grants	1,254,550
Grants (in Dollars per share)	$ 1.90
Grants	2 years 6 months
Exercised	0
Canceled	0

NOTE 10 - FAIR VALUE MEASUREM41

NOTE 10 - FAIR VALUE MEASUREMENT (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Embedded Derivative, Fair Value of Embedded Derivative Liability	$ 291,086	$ 285,157	$ 1,242,590
Derivative Liability, Current	$ 2,324,460	$ 1,621,199	$ 4,097,444

NOTE 10 - FAIR VALUE MEASUREM42

NOTE 10 - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Total (gains) losses
Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016	$ 17,771	$ 2,851,755	$ (807,087)	$ 3,050,318
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2015	1,621,199		1,621,199
Total (gains) losses
Transfers out due to conversion of Series C Preferred Stock			0
Mark to market to September 30, 2016			703,261
Balance, September 30, 2016			2,324,460
Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016			(703,261)
Embedded Derivative Financial Instruments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2015	$ 285,157		285,157
Total (gains) losses
Transfers out due to conversion of Series C Preferred Stock			(97,897)
Mark to market to September 30, 2016			103,826
Balance, September 30, 2016			291,086
Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016			$ (103,826)

NOTE 11 - SUBSEQUENT EVENTS (De

NOTE 11 - SUBSEQUENT EVENTS (Details) - USD ($)	Oct. 28, 2016	Oct. 16, 2016	Sep. 30, 2016
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Value, Issued for Services			$ 2,471,050
Stock Issued During Period, Shares, New Issues			2,208,514
Class of Warrant or Rights, Granted			1,254,550
Proceeds from Issuance or Sale of Equity			$ 3,053,868
Payments of Stock Issuance Costs			$ 278,188
Subsequent Event [Member]
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services		15,000
Stock Issued During Period, Value, Issued for Services		$ 22,800
Stock Issued During Period, Shares, New Issues	346,567
Class of Warrant or Rights, Granted	173,284
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50
Warrants, Term of Warrants	3 years
Proceeds from Issuance or Sale of Equity	$ 450,477
Payments of Stock Issuance Costs	$ 69,373